CONSTELLATION PHARMCETICLS I's ticker is CNST and the CUSIP is 210373106. A total of 50 filers reported holding CONSTELLATION PHARMCETICLS I in Q2 2019. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $45,326,000 | +7.7% | 1,341,000 | -25.5% | 1.15% | -8.2% |
| Q1 2021 | $42,102,000 | -18.1% | 1,800,000 | +0.8% | 1.25% | -17.7% |
| Q4 2020 | $51,408,000 | +158.9% | 1,785,000 | +82.1% | 1.52% | +71.3% |
| Q3 2020 | $19,855,000 | -32.6% | 980,000 | 0.0% | 0.89% | -49.0% |
| Q2 2020 | $29,449,000 | -4.4% | 980,000 | 0.0% | 1.74% | -46.7% |
| Q1 2020 | $30,801,000 | -46.1% | 980,000 | -19.2% | 3.27% | -37.8% |
| Q4 2019 | $57,132,000 | -99.4% | 1,212,734 | -20.4% | 5.25% | +415.6% |
| Q3 2019 | $9,844,782,000 | -47.4% | 1,523,960 | 0.0% | 1.02% | -41.8% |
| Q2 2019 | $18,714,229,000 | +88605.6% | 1,523,960 | -2.1% | 1.75% | -24.4% |
| Q1 2019 | $21,097,000 | +237.9% | 1,556,999 | +0.0% | 2.32% | +116.9% |
| Q4 2018 | $6,244,000 | -29.4% | 1,556,998 | +18.4% | 1.07% | -0.7% |
| Q3 2018 | $8,848,000 | – | 1,314,743 | – | 1.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 1,574,229 | $36,821,000 | 28.20% |
| Ponoi Management, LLC | 1,880,623 | $43,988,000 | 25.87% |
| VR Adviser, LLC | 4,016,873 | $93,955,000 | 10.19% |
| Column Group LLC | 2,626,631 | $61,437,000 | 5.89% |
| Euclidean Capital LLC | 554,325 | $12,966,000 | 4.34% |
| GREAT POINT PARTNERS LLC | 872,415 | $20,406,000 | 4.22% |
| Venrock Management V, LLC | 1,570,058 | $36,724,000 | 3.76% |
| COMMODORE CAPITAL LP | 368,448 | $8,618,000 | 3.43% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 621,541 | $14,538,000 | 1.90% |
| Bain Capital Life Sciences Investors, LLC | 1,400,000 | $32,746,000 | 1.86% |